162 related articles for article (PubMed ID: 17103075)
1. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
[TBL] [Abstract][Full Text] [Related]
2. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
[TBL] [Abstract][Full Text] [Related]
3. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
[TBL] [Abstract][Full Text] [Related]
4. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
5. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
[TBL] [Abstract][Full Text] [Related]
6. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
7. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
9. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
[TBL] [Abstract][Full Text] [Related]
10. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
[TBL] [Abstract][Full Text] [Related]
11. [The safety of perioperative bevacizumab use].
Mariani P
J Chir (Paris); 2010 Jan; 147 Suppl 1():S12-7. PubMed ID: 20172200
[TBL] [Abstract][Full Text] [Related]
12. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases.
Neeff HP; Drognitz O; Klock A; Illerhaus G; Opitz OG; Hopt UT; Makowiec F
Int J Colorectal Dis; 2012 May; 27(5):635-45. PubMed ID: 22139030
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
14. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
[TBL] [Abstract][Full Text] [Related]
15. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
[TBL] [Abstract][Full Text] [Related]
16. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS
J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases.
Petrelli NJ
J Clin Oncol; 2009 Apr; 27(11):1917; author reply 1918. PubMed ID: 19255304
[No Abstract] [Full Text] [Related]
18. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
[TBL] [Abstract][Full Text] [Related]
19. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.
Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P
World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754
[TBL] [Abstract][Full Text] [Related]
20. Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?
Bilchik AJ; Hecht JR
J Clin Oncol; 2008 Apr; 26(11):1786-8. PubMed ID: 18398144
[No Abstract] [Full Text] [Related]
[Next] [New Search]